Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).

Cracking the Nutritional Puzzle: A Path Out Of Dallas’ Food Desert

Recently, I was shocked to hear that North Texas is one of the hardest-hit areas of the country for food insecurity. Shocked, but not surprised.

July 29, 2024

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Rapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing

October 14, 2024

Cerebral to Pay $3.6M Settlement Over Unauthorized Distribution of Controlled Substances

What You Should Know: – Cerebral, Inc., an online mental healthcare provider, has entered into a non-prosecution agreement (NPA) with the U.S. Attorney’s Office for

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.